Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AcroPass Acne Cure is a dissolving microneedle patch developed by Raphas for the treatment of acne vulgaris. The product utilizes the company's proprietary Droplet Extension (DEN) technology, which allows for the manufacture of microneedles at room temperature, preserving the stability and efficacy of active ingredients. The patch features microscopic needles composed primarily of hyaluronic acid and medicinal compounds such as salicylic acid. Upon application, these needles penetrate the stratum corneum to deliver the active ingredients directly into the acne lesion, where they dissolve and release their payload. AcroPass Acne Cure is approved as a quasi-drug by the South Korean Ministry of Food and Drug Safety (MFDS) for its keratolytic and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AcroPass Acne Cure.